The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...

The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...

Today, the first monoclonal antibodies, lecanemab and donanemab ... lecanemab and donanemab continue their phase III clinical ...

Most discontinued anti-tau antibodies (red) targeted tau’s N-terminus. Of the antibodies currently in trials (green), bepranemab and E2814 presented results at CTAD, while JJ-63733657/posdinemab and ...

We asked Dr. Joanne Pike, CEO of the Alzheimer's Association to help explain the challenges and hopes when it comes to this debilitating disease.

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

With the approval of anti-amyloid monoclonal antibodies to treat early-stage Alzheimer’s disease (AD), the need for accurate and early diagnosis is crucial. Blood-based biomarkers offer a ...

Then in 1890, Emil von Behring made the remarkable discovery serum derived from the blood of horses injected with diphtheria toxin contains an “antitoxin” that can be used to protect against as well ...

driven by monoclonal antibodies like Aducanumab and Leqembi, which offer potential disease-modifying effects for advanced Alzheimer's stages. Alzheimer's Drugs Market Analysis by Distribution ...

The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness watchdog, NICE, said the drug isn't cost-effective.

Eisai (ESAIY) and Biogen (BIIB) announced that a positive opinion has been received from the Committee for Medicinal Products for Human Use of ...